首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1402920

血友病治疗药物市场（产品：重组凝血因子浓缩物、血浆衍生凝血因子浓缩物等）- 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日期: 2023年11月28日 | 出版商:

Transparency Market Research | 英文 188 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

血友病治疗药物市场 - 报告范围

TMR 关于全球血友病治疗药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球血友病治疗药物的收入2017-2031年期间的市场，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球血友病治疗药物市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解血友病治疗药物市场。

市场概况
2023年市场价值	118 亿美元
2031 年市场价值	186 亿美元
CAGR	5%

该报告深入探讨了全球血友病治疗药物市场的竞争格局。全球血友病治疗药物市场的主要参与者已经确定，并且每个参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球血友病治疗药物市场参与者的属性。

TMR's report on the global hemophilia treatment drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hemophilia treatment drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hemophilia treatment drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hemophilia treatment drugs market.

Market Snapshot
Market Value in 2023	US$ 11.8 Bn
Market Value in 2031	US$ 18.6 Bn
CAGR	5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hemophilia treatment drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hemophilia treatment drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hemophilia treatment drugs market.

The report delves into the competitive landscape of the global hemophilia treatment drugs market. Key players operating in the global hemophilia treatment drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hemophilia treatment drugs market profiled in this report.

Key Questions Answered in Global hemophilia treatment drugs Market Report:

What is the sales/revenue generated by hemophilia treatment drugs across all regions during the forecast period?
What are the opportunities in the global hemophilia treatment drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Hemophilia Treatment Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global hemophilia treatment drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hemophilia treatment drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hemophilia treatment drugs market.

1. Executive Summary

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemophilia Treatment Drugs Market

4. Market Overview

4.1. Market Segmentation
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. List of Types of Hemophilia Treatment Drugs
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
5.4. COVID-19 Pandemic Impact on Industry

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2023-2031
- 6.3.1. Recombinant Coagulation Factor Concentrates
  - 6.3.1.1. Factor VIII
  - 6.3.1.2. Factor IX
  - 6.3.1.3. Others
- 6.3.2. Plasma-derived Coagulation Factor Concentrates
  - 6.3.2.1. Factor VIII
  - 6.3.2.2. Factor IX
  - 6.3.2.3. Others
- 6.3.3. Others
6.4. Market Attractiveness, by Product

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2023-2031
- 7.3.1. Hemophilia A
- 7.3.2. Hemophilia B
- 7.3.3. Others
7.4. Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2023-2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023-2031
- 10.2.1. Recombinant Coagulation Factor Concentrates
  - 10.2.1.1. Factor VIII
  - 10.2.1.2. Factor IX
  - 10.2.1.3. Others
- 10.2.2. Plasma-derived Coagulation Factor Concentrates
  - 10.2.2.1. Factor VIII
  - 10.2.2.2. Factor IX
  - 10.2.2.3. Others
- 10.2.3. Others
10.3. Market Attractiveness, by Product
10.4. Market Value Forecast, by Disease Indication, 2023-2031
- 10.4.1. Hemophilia A
- 10.4.2. Hemophilia B
- 10.4.3. Others
10.5. Market Attractiveness, by Disease Indication
10.6. Market Value Forecast, by Distribution Channel, 2023-2031
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
10.7. Market Attractiveness, by Distribution Channel
10.8. Market Value Forecast, by Country, 2023-2031
- 10.8.1. U.S.
- 10.8.2. Canada
10.9. Market Attractiveness Analysis
- 10.9.1. By Product
- 10.9.2. By Disease Indication
- 10.9.3. By Distribution Channel
- 10.9.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
- 11.1.2. Recombinant Coagulation Factor Concentrates
  - 11.1.2.1. Factor VIII
  - 11.1.2.2. Factor IX
  - 11.1.2.3. Others
- 11.1.3. Plasma-derived Coagulation Factor Concentrates
  - 11.1.3.1. Factor VIII
  - 11.1.3.2. Factor IX
  - 11.1.3.3. Others
- 11.1.4. Others
11.2. Market Attractiveness, by Product
11.3. Market Value Forecast, by Disease Indication, 2023-2031
- 11.3.1. Hemophilia A
- 11.3.2. Hemophilia B
- 11.3.3. Others
11.4. Market Attractiveness, by Disease Indication
11.5. Market Value Forecast, by Distribution Channel, 2023-2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Attractiveness, by Distribution Channel
11.7. Market Value Forecast, by Country/Sub-region, 2023-2031
- 11.7.1. Germany
- 11.7.2. U.K.
- 11.7.3. France
- 11.7.4. Italy
- 11.7.5. Spain
- 11.7.6. Rest of Europe
11.8. Market Attractiveness Analysis
- 11.8.1. By Product
- 11.8.2. By Disease Indication
- 11.8.3. By Distribution Channel
- 11.8.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023-2031
- 12.2.1. Recombinant Coagulation Factor Concentrates
  - 12.2.1.1. Factor VIII
  - 12.2.1.2. Factor IX
  - 12.2.1.3. Others
- 12.2.2. Plasma-derived Coagulation Factor Concentrates
  - 12.2.2.1. Factor VIII
  - 12.2.2.2. Factor IX
  - 12.2.2.3. Others
- 12.2.3. Others
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Disease Indication, 2023-2031
- 12.4.1. Hemophilia A
- 12.4.2. Hemophilia B
- 12.4.3. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Distribution Channel, 2023-2031
- 12.6.1. Hospital Pharmacies
- 12.6.2. Retail Pharmacies
- 12.6.3. Online Pharmacies
12.7. Market Attractiveness, by Distribution Channel
12.8. Market Value Forecast, by Country/Sub-region, 2023-2031
- 12.8.1. China
- 12.8.2. Japan
- 12.8.3. India
- 12.8.4. Australia & New Zealand
- 12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
- 12.9.1. By Product
- 12.9.2. By Disease Indication
- 12.9.3. By Distribution Channel
- 12.9.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023-2031
- 13.2.1. Recombinant Coagulation Factor Concentrates
  - 13.2.1.1. Factor VIII
  - 13.2.1.2. Factor IX
  - 13.2.1.3. Others
- 13.2.2. Plasma-derived Coagulation Factor Concentrates
  - 13.2.2.1. Factor VIII
  - 13.2.2.2. Factor IX
  - 13.2.2.3. Others
- 13.2.3. Others
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Disease Indication, 2023-2031
- 13.4.1. Hemophilia A
- 13.4.2. Hemophilia B
- 13.4.3. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Distribution Channel, 2023-2031
- 13.6.1. Hospital Pharmacies
- 13.6.2. Retail Pharmacies
- 13.6.3. Online Pharmacies
13.7. Market Attractiveness, by Distribution Channel
13.8. Market Value Forecast, by Country/Sub-region, 2023-2031
- 13.8.1. Brazil
- 13.8.2. Mexico
- 13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
- 13.9.1. By Product
- 13.9.2. By Disease Indication
- 13.9.3. By Distribution Channel
- 13.9.4. By Country/Sub-region

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023-2031
- 14.2.1. Recombinant Coagulation Factor Concentrates
  - 14.2.1.1. Factor VIII
  - 14.2.1.2. Factor IX
  - 14.2.1.3. Others
- 14.2.2. Plasma-derived Coagulation Factor Concentrates
  - 14.2.2.1. Factor VIII
  - 14.2.2.2. Factor IX
  - 14.2.2.3. Others
- 14.2.3. Others
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Disease Indication, 2023-2031
- 14.4.1. Hemophilia A
- 14.4.2. Hemophilia B
- 14.4.3. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Distribution Channel, 2023-2031
- 14.6.1. Hospital Pharmacies
- 14.6.2. Retail Pharmacies
- 14.6.3. Online Pharmacies
14.7. Market Attractiveness, by Distribution Channel
14.8. Market Value Forecast, by Country/Sub-region, 2023-2031
- 14.8.1. GCC Countries
- 14.8.2. South Africa
- 14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
- 14.9.1. By Product
- 14.9.2. By Disease Indication
- 14.9.3. By Distribution Channel
- 14.9.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
- 15.3.1. Pfizer Inc.
  - 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. Financial Overview
  - 15.3.1.4. SWOT Analysis
  - 15.3.1.5. Strategic Overview
- 15.3.2. CSL Behring
  - 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. Financial Overview
  - 15.3.2.4. SWOT Analysis
  - 15.3.2.5. Strategic Overview
- 15.3.3. Kedrion
  - 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. Financial Overview
  - 15.3.3.4. SWOT Analysis
  - 15.3.3.5. Strategic Overview
- 15.3.4. Takeda Pharmaceutical Company Limited
  - 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. Financial Overview
  - 15.3.4.4. SWOT Analysis
  - 15.3.4.5. Strategic Overview
- 15.3.5. Novo Nordisk A/S
  - 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. Financial Overview
  - 15.3.5.4. SWOT Analysis
  - 15.3.5.5. Strategic Overview
- 15.3.6. Bayer AG
  - 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. Financial Overview
  - 15.3.6.4. SWOT Analysis
  - 15.3.6.5. Strategic Overview
- 15.3.7. F. Hoffmann-La Roche Ltd.
  - 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. Financial Overview
  - 15.3.7.4. SWOT Analysis
  - 15.3.7.5. Strategic Overview
- 15.3.8. Octapharma AG
  - 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. Financial Overview
  - 15.3.8.4. SWOT Analysis
  - 15.3.8.5. Strategic Overview
- 15.3.9. Biotest AG
  - 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. Financial Overview
  - 15.3.9.4. SWOT Analysis
  - 15.3.9.5. Strategic Overview
- 15.3.10. Sanofi S.A.
  - 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. Financial Overview
  - 15.3.10.4. SWOT Analysis
  - 15.3.10.5. Strategic Overview

简介目录图表

List of Tables

Table 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 2: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 3: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
Table 4: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Region, 2023-2031
Table 5: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country, 2023-2031
Table 6: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 7: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 8: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
Table 9: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
Table 10: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 11: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 12: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
Table 13: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
Table 14: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 15: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 16: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
Table 17: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
Table 18: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 19: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 20: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
Table 21: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
Table 22: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
Table 23: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
Table 24: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031

List of Figures

Figure 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
Figure 2: Global Hemophilia Treatment Drugs Market Value Share, by Product, 2022
Figure 3: Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2022
Figure 4: Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2022
Figure 5: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 6: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 7: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 8: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
Figure 9: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 10: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 11: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 12: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 13: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
Figure 14: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 15: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 16: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 17: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 18: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 19: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
Figure 20: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 21: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 22: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
Figure 23: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 25: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 26: Europe America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 27: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 28: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
Figure 29: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 30: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 31: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
Figure 32: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 35: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 36: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 37: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
Figure 38: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 39: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 40: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
Figure 41: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 43: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 44: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 45: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 46: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
Figure 47: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 49: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 50: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 51: Middle East & Africa America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2023-2031
Figure 52: Middle East & Africa America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
Figure 53: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 54: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 55: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2022)